In April, Alexis McKee, MD; Janet B. McGill, MD; and current fellow, Kai Jones, MD, had their letter to the editor titled “Insulin Dosing Safety in CKD,” published in volume 8, issue 4 of Kidney International Reports.
In the letter, the authors highlight a recent manuscript discussing the use of glucose-lowering agents for persons with diabetes and chronic kidney disease (CKD). In response to the paper, they request clarification of “the recommended starting doses and usual insulin doses for persons with type 1 diabetes and type 2 diabetes, to avoid potential overdose and hypoglycemia.”
Their letter to the editor highlights the importance of carefully reviewing literature prior to reprinting tables from prior publications containing incorrect information. The peer review process of publication is of the utmost importance in scientific literature.
Alexis M. McKee, Kai E. Jones, Janet B. McGill. Insulin Dosing Safety in CKD, Kidney International Reports. Volume 8. Issue 4. 2023. Page 947. ISSN 2468-0249, https://doi.org/10.1016/j.ekir.2023.01.032